Tonix Pharmaceuticals Holding (TNXP) Total Liabilities (2010 - 2026)

Tonix Pharmaceuticals Holding's Total Liabilities history runs 17 years deep, the most recent figure standing at $30.8 million for Q1 2026.

• On a quarterly basis, Total Liabilities rose 146.71% year-over-year to $30.8 million in Q1 2026; TTM through Mar 2026 was $30.8 million, a 146.71% increase from a year earlier, with the FY2025 full-year figure at $32.0 million, up 37.24% from the prior year.
• Total Liabilities fell to $30.8 million in Q1 2026 per TNXP's latest filing, from $32.0 million in the prior quarter.
• Across five years, Total Liabilities topped out at $48.9 million in Q4 2023 and bottomed at $12.5 million in Q1 2025.
• The 5-year median for Total Liabilities is $19.4 million (2025), against an average of $22.4 million.
• Across the five-year window, Total Liabilities soared 164.38% in 2023 and slumped 54.14% in 2025, its largest moves.
• Year by year, Total Liabilities stood at $18.5 million in 2022, then surged by 164.38% to $48.9 million in 2023, then tumbled by 52.32% to $23.3 million in 2024, then soared by 37.24% to $32.0 million in 2025, then declined by 3.89% to $30.8 million in 2026.
• Per Business Quant, the three latest TNXP Total Liabilities figures stand at $30.8 million (Q1 2026), $32.0 million (Q4 2025), and $21.3 million (Q3 2025).